Baxter (BAX) (CFN) (PLCM) (ELNK) (CMI) (OHI) Ratings, Price Targets

Baxter International Inc. (NYSE: BAX), CareFusion Co. (NYSE: CFN), Polycom (NASDAQ: PLCM), EarthLink (NASDAQ: ELNK), Cummins (NYSE: CMI) and Omega Healthcare Investors, Inc. (NYSE: OHI) ratings and price targets.

Baxter International Inc. (BAX) had its “Overweight” rating reiterated by Morgan Stanley (NYSE:MS).

CareFusion Co. (CFN) had its “Buy” rating reiterated by Citigroup (NYSE:C). They have a price target of $28.00 on the company.

Polycom (PLCM) had its “Neutral” rating reiterated by Goldman Sachs (NYSE:GS). They have a price target of $21.00 on the company.

Stephens initiated coverage on EarthLink (ELNK). They placed an “Overweight” rating on the company.

Cummins (CMI) was downgraded by Standpoint Research from a “Buy” rating to a “Hold” rating.

Omega Healthcare Investors, Inc. (OHI) was downgraded by JMP Securities from an “Outperform” rating to a “Market Perform” rating.

Tyson (TSN) (MGM) (JNJ) (CFN) (CREE) (MRX) EPS Estimates Changed

Tyson Foods, Inc. (NYSE: TSN), MGM Resorts (NYSE: MGM), Johnson & Johnson (NYSE: JNJ), CareFusion Co. (NYSE: CFN), Cree, Inc. (NASDAQ: CREE) and Medicis Pharmaceutic (NYSE: MRX) EPS estimates adjusted by analysts.

Morgan Stanley (NYSE:MS) raised its EPS estimates on Tyson Foods, Inc. (TSN). They have an “Equal Weight” rating on the company.

Morgan Stanley raised its EPS estimates on MGM Resorts (MGM). They have an “Equal Weight” rating and a price target of $17.00 on the company.

Goldman Sachs (NYSE:GS) slashed its EPS estimates on Johnson & Johnson (JNJ). They have a “Buy” rating and a price target of $74.00 on the company.

Citigroup (NYSE:C) lowered its EPS estimates on CareFusion Co. (CFN). They have a “Buy” rating and a price target of $31.00 on the company.

UBS AG (NYSE:UBS) cuts its EPS estimates on Cree, Inc. (CREE). They have a “Neutral” rating and a price target of $30.00 on the company. They had a price target of $41.00 on the company before. They cited valuation as the catalyst behind the call.

UBS AG cut its EPS estimates on Medicis Pharmaceutic (MRX). They have a “Neutral” rating and a price target of $39.00 on the company.